We are live on
!
Find out more
BC
Broadfin Capital Portfolio holdings
AUM
$747M
1-Year Est. Return
100.56%
This Fund
S&P 500
This Quarter
Est. Return
+9.97%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$642M
AUM Growth
+$30M
(+4.9%)
Cap. Flow
-$8.58M
Cap. Flow
% of AUM
-1.34%
Top 10 Holdings %
Top 10 Hldgs %
52.02%
Holding
62
New
16
Increased
10
Reduced
19
Closed
11
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ADMS
Adamas Pharmaceuticals
ADMS
|
+$35.8M |
| 2 |
LJPC
La Jolla Pharmaceutical Company
LJPC
|
+$20.2M |
| 3 |
KALA BIO
KALA
|
+$10.4M |
| 4 |
AMAG
AMAG Pharmaceuticals
AMAG
|
+$10.1M |
| 5 |
NUVA
NuVasive, Inc.
NUVA
|
+$8.93M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RXDX
Ignyta, Inc.
RXDX
|
+$30.7M |
| 2 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$27.9M |
| 3 |
Iovance Biotherapeutics
IOVA
|
+$21.6M |
| 4 |
ENDP
Endo International plc
ENDP
|
+$18.9M |
| 5 |
AngioDynamics
ANGO
|
+$13.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 87.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Alphatec Holdings
ATEC
$1.27B
| – | – |
-145,514
| Closed | -$387K |
|
52
Baxter International
BAX
$11.6B
| – | – |
-65,300
| Closed | -$4.22M |
|
|
RGLS
53
DELISTED
Regulus Therapeutics
RGLS
| – | – |
-12,578
| Closed | -$1.57M |
|
54
CALL
Travere Therapeutics
TVTX
$5.33B
| – | – |
-51,900
| Closed | -$1.09M |
|
|
NSTG
55
DELISTED
NanoString Technologies, Inc.
NSTG
| – | – |
-100,000
| Closed | -$747K |
|
|
ACGN
56
DELISTED
Aceragen Inc
ACGN
| – | – |
-14,946
| Closed | -$4.29M |
|
|
AGRX
57
DELISTED
Agile Therapeutics
AGRX
| – | – |
-179
| Closed | -$964K |
|
|
ENDP
58
DELISTED
Endo International plc
ENDP
| – | – |
-2,442,323
| Closed | -$18.9M |
|
|
MDCO
59
DELISTED
Medicines Co
MDCO
| – | – |
-366,300
| Closed | -$10M |
|
|
CGNT
60
DELISTED
Cogentix Medical, Inc.
CGNT
| – | – |
-670,812
| Closed | -$2.11M |
|
|
RXDX
61
DELISTED
Ignyta, Inc.
RXDX
| – | – |
-1,150,119
| Closed | -$30.7M |
|
Similar funds
CBU
CONA
MP
SC
KGACF
BPWA
TRAM
VMI
Broadfin Capital's Q1 2018 Portfolio in Review
As of Q1 2018, Broadfin Capital held 62 positions worth $642M, up 4.9% from $612M the previous quarter. Its ten largest holdings account for 52% of the portfolio.
Broadfin Capital's Q1 2018 filing shows 16 new, 10 increased, 19 reduced and 11 closed positions. Its largest new stake was Adamas Pharmaceuticals: 1,135,203 shares worth $27.1M. The largest sale was Ignyta, Inc., an estimated $30.7M.
By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 92% a quarter earlier.
- Broadfin Capital's largest Q1 2018 buy was Adamas Pharmaceuticals: 1,135,203 shares worth $27.1M.
- Broadfin Capital added most to La Jolla Pharmaceutical Company in Q1 2018, an estimated $20.2M increase.
- Broadfin Capital's biggest Q1 2018 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $27.9M.
- Broadfin Capital fully exited Ignyta, Inc. in Q1 2018, selling an estimated $30.7M.
- Broadfin Capital's ten largest holdings make up 52% of its $642M portfolio in Q1 2018.
- Broadfin Capital opened 16 new positions and closed 11 in Q1 2018.
- Broadfin Capital's portfolio value rose 4.9% quarter-over-quarter to $642M.
Based on Broadfin Capital's 13F filing for Q1 2018, filed 14 May 2018.